Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized
functions in immune regulation. Immunity. 2016;44(5):989-1004.
Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells.
Front Immunol. 2013;4:449. doi:10.3389/fimmu.2013.00449.
Nakayama M, Akiba H, Takeda K, et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.
Blood. 2009;113(16):3821-3830.
Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine
receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235(1):172-189.
Maurya N, Gujar R, Gupta M, Yadav V, Verma S, Sen P. Immunoregulation of dendritic cells by the receptor T
cell Ig and mucin protein-3 via Bruton's tyrosine kinase and c-Src. J Immunol. 2014;193(7):3417-3425.
Chiba S, Baghdadi M, Akiba H, et al. Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune
responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol.
2012;13(9):832-842.
Dardalhon V, Anderson AC, Karman J, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through
promotion of CD11b+Ly-6G+ myeloid cells. J Immunol. 2010;185(3):1383-1392.
Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor
antigen–specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175-2186.
Zhang Y, Cai P, Li L, et al. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal
cancer patients. Int Immunopharmacol. 2017;43:210-218.
Gautron A-S, Dominguez-Villar M, de Marcken M, Hafler DA. Enhanced suppressor function of TIM-3+FoxP3+
regulatory T cells. Eur J Immunol. 2014;44(9):2703-2711.
da Silva IP, Gallois A, Jimenez-Baranda S, et al. Reversal of NK-cell exhaustion in advanced melanoma by
Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410-422.
Weber JK, Zhou R. Phosphatidylserine-induced conformational modulation of immune cell exhaustion-associated
receptor TIM3. Sci Rep. 2017;7:13579. doi:10.1038/s41598-017-14064-x.
Anderson AC. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res.
2014;2(5):393-398.
Lee J, Ahn E, Kissick HT, Ahmed R. Reinvigorating exhausted T cells by blockade of the PD-1 pathway. For
Immunopathol Dis Therap. 2015;6(1-2):7-17.
Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to
reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187-2194.